Author

John Lynch

MANAGEMENT AND UNMET NEED AMONGST MILD AND MODERATE/ SEVERE CD AND UC PATIENTS: FINDINGS FROM A CROSS SECTIONAL STUDY IN THE US AND FRANCE, GERMANY, ITALY, SPAIN, UK (EU5)
MANAGEMENT AND UNMET NEED AMONGST MILD AND MODERATE/ SEVERE CD AND UC PATIENTS: FINDINGS FROM A CROSS SECTIONAL STUDY IN THE US AND FRANCE, GERMANY, ITALY, SPAIN, UK (EU5)

John Lynch  et al.

CORTICOSTEROID USE AND THE ASSOCIATED IMPACT ON PATIENTS WITH CROHN'S DISEASE (CD) AND ULCERATIVE COLITIS (UC) IN THE US, FRANCE, GERMANY, ITALY, SPAIN, AND UK (EU5)
CORTICOSTEROID USE AND THE ASSOCIATED IMPACT ON PATIENTS WITH CROHN'S DISEASE (CD) AND ULCERATIVE COLITIS (UC) IN THE US, FRANCE, GERMANY, ITALY, SPAIN, AND UK (EU5)

John Lynch  et al.

HUMANISTIC BURDEN AND IMPACT OF THE DISEASE IN MODERATE TO SEVERE PATIENTS WITH CROHN'S DISEASE (CD) AND ULCERATIVE COLITIS (UC): FINDINGS FROM A CROSS SECTIONAL STUDY IN THE US AND FRANCE, GERMANY, ITALY, SPAIN, UK (EU5)
HUMANISTIC BURDEN AND IMPACT OF THE DISEASE IN MODERATE TO SEVERE PATIENTS WITH CROHN'S DISEASE (CD) AND ULCERATIVE COLITIS (UC): FINDINGS FROM A CROSS SECTIONAL STUDY IN THE US AND FRANCE, GERMANY, ITALY, SPAIN, UK (EU5)

John Lynch  et al.

EFFICACY AND SAFETY OF USTEKINUMAB FOR CROHN'S DISEASE THROUGH 5 YEARS: FINAL RESULTS FROM THE IM-UNITI LONG-TERM EXTENSION
EFFICACY AND SAFETY OF USTEKINUMAB FOR CROHN'S DISEASE THROUGH 5 YEARS: FINAL RESULTS FROM THE IM-UNITI LONG-TERM EXTENSION

John Lynch  et al.

AGREEMENT BETWEEN LOCALLY AND CENTRALLY REVIEWED MAYO ENDOSCOPIC SUBSCORES IN THE UNIFI STUDY OF USTEKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS: CORROBORATION WITH FECAL CALPROTECTIN AND HISTOLOGY
AGREEMENT BETWEEN LOCALLY AND CENTRALLY REVIEWED MAYO ENDOSCOPIC SUBSCORES IN THE UNIFI STUDY OF USTEKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS: CORROBORATION WITH FECAL CALPROTECTIN AND HISTOLOGY

John Lynch  et al.

SAFETY OF USTEKINUMAB IN OLDER IBD PATIENTS (>=60 YEARS): POOLED SAFETY ANALYSIS THROUGH 5 YEARS IN CD AND 2 YEARS IN UC AND ALL APPROVED INDICATIONS
SAFETY OF USTEKINUMAB IN OLDER IBD PATIENTS (>=60 YEARS): POOLED SAFETY ANALYSIS THROUGH 5 YEARS IN CD AND 2 YEARS IN UC AND ALL APPROVED INDICATIONS

John Lynch  et al.

Item 1 - 6 / 6
1